Abstract:Background: Alzheimer disease (AD) affects at least 5 million individuals in the USA alone stimulating an intense search for disease prevention and treatment therapies as well as for diagnostic techniques allowing early identification of AD during a long pre-symptomatic period that can be used for the initiation of prevention trials of disease-modifying therapies in asymptomatic individuals.Methods: Our approach to developing such techniques is based on the Gradient Echo Plural Contrast Imaging (GEPCI) technique that provides quantitative in vivo measurements of several brain-tissue-specific characteristics of the gradient echo MRI signal (GEPCI metrics) that depend on the integrity of brain tissue cellular structure.Preliminary data were obtained from 34 participants selected from the studies of aging and dementia at the Knight Alzheimer's Disease Research Center at Washington University in St. Louis. Cognitive status was operationalized with the Clinical Dementia Rating (CDR) scale. The participants, assessed as cognitively normal (CDR=O; n=23) or with mild AD dementia (CDR=0.5 or 1; n=11) underwent GEPCI MRI, a collection of cognitive performance tests and CSF amyloid (A beta) biomarker A beta(42). A subset of 19 participants also underwent PET PiB studies to assess their brain A beta burden. According to the Ap status, cognitively normal participants were divided into normal (A beta negative; n=13) and preclinical (A beta positive; n=10) groups.Results: GEPCI quantitative measurements demonstrated significant differences between all the groups: normal and preclinical, normal and mild AD, and preclinical and mild AD. GEPCI quantitative metrics characterizing tissue cellular integrity in the hippocampus demonstrated much stronger correlations with psychometric tests than the hippocampal atrophy. Importantly, GEPCI-determined changes in the hippocampal tissue cellular integrity were detected even in the hippocampal areas not affected by the atrophy.Our studies also uncovered strong correlations between GEPCI brain tissue metrics and beta-amyloid (A(3) burden defined by positron emission tomography (PET) - the current in vivo gold standard for detection of cortical All, thus supporting GEPCI as a potential surrogate marker for All imaging a known biomarker of early AD. Remarkably, the data show significant correlations not only in the areas of high A beta accumulation (e.g. precuneus) but also in some areas of medial temporal lobe (e.g. parahippocampal cortex), where A beta accumulation is relatively low.Conclusion: We have demonstrated that GEPCI provides a new approach for the in vivo evaluation of AD related tissue pathology in the preclinical and early symptomatic stages of AD. Since MRI is a widely available technology, the GEPCI surrogate markers of AD pathology have a potential for improving the quality of AD diagnostic, and the evaluation of new disease-modifying therapies.

Abnormal motor cortical plasticity as a useful neurophysiological biomarker for Alzheimer's disease pathology

Temporal Dynamic Changes of Intrinsic Brain Activity Associated with Cognitive Reserve in Prodromal Alzheimer's Disease.

Distinct Brain Functional Impairment Patterns Between Suspected Non-Alzheimer Disease Pathophysiology and Alzheimer’s Disease: A Study Combining Static and Dynamic Functional Magnetic Resonance Imaging

Cortical Plasticity is Correlated with Cognitive Improvement in Alzheimer’s Disease Patients after Rtms Treatment

Distinct Spontaneous Brain Activity Patterns in Different Biologically-Defined Alzheimer's Disease Cognitive Stage: A Preliminary Study.

Cortical excitability and plasticity in Alzheimer’s disease and mild cognitive impairment: A systematic review and meta-analysis of transcranial magnetic stimulation studies

Neurophysiological Signatures of Cognitive Impairment Based on Cortical Plasticity and Cholinergic Modulation

Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer's Disease-Modifying Therapy

Transcranial magnetic stimulation in Alzheimer’s disease: a neurophysiological marker of cortical hyperexcitability

Alzheimer's disease biomarker burden in primary motor cortices is associated with poorer dexterity performance

Transcranial Magnetic Stimulation for the Assessment of Neurodegenerative Disease

Statistical Parametric Mapping in Amyloid Positron Emission Tomography

P14: How does dorsolateral prefrontal cortex plasticity differ across the Alzheimer's disease spectrum?

Resting-State Co-activation Patterns as Promising Candidates for Prediction of Alzheimer’s Disease in Aged Mice

In Vivo Detection of Microstructural Correlates of Brain Pathology in Preclinical and Early Alzheimer Disease with Magnetic Resonance Imaging.

Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease

Application of Repetitive Transcranial Magnetic Stimulation over the Dorsolateral Prefrontal Cortex in Alzheimer’s Disease: A Pilot Study

Multimodal analysis using [11C]PiB-PET/MRI for functional evaluation of patients with Alzheimer's disease

Synergistic association of Aβ and tau pathology with cortical neurophysiology and cognitive decline in asymptomatic older adults

Functional Neurophysiological Biomarkers of Early‐Stage Alzheimer’s Disease: An Experimental Perspective of Network Hyperexcitability in Disease Progression and Pharmacological Interventions

Motor cortical excitability predicts cognitive phenotypes in amyotrophic lateral sclerosis